LYTGOBI

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Lithuania.

Active ingredients

The drug LYTGOBI contains one active pharmaceutical ingredient (API):

1	Futibatinib UNII 4B93MGE4AL - FUTIBATINIB
	Constitutive fibroblast growth factor receptor (FGFR) signalling can support the proliferation and survival of malignant cells. Futibatinib is a tyrosine kinase inhibitor that irreversibly inhibits FGFR 1, 2, 3, and 4 by covalent binding.
	Read more about Futibatinib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LYTGOBI Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01EN04		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EN Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors
Discover more medicines within L01EN04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3035090, 3035102, 3035113
FR	Base de données publique des médicaments	68552628
IT	Agenzia del Farmaco	050756016, 050756028, 050756030
LT	Valstybinė vaistų kontrolės tarnyba	1097365, 1097366, 1097367
US	FDA, National Drug Code	64842-0120